340bemployed.org

Your Free Source for 340B News and Commentary

  • Home
  • About Us
  • Employers
  • Job Seekers
  • Advertise
  • 340B Health

Big Pharma Plays the Blame Game on Drug Prices


 

Print Article

March 2, 2017—If you’re in business, it’s bad news when the president of the United States asks a joint session of Congress on national TV to do something immediately about your “artificially high” prices.

That’s the situation Big Pharma is in today. President Trump’s jab about its price gouging in his Feb. 28 congressional address is just the latest he’s taken at the industry. The media is piling on, too. Every day there’s another headline about a drug company gaming the system to goose its profits or a patient forced to choose between obscenely expensive medicine and food, clothing, and shelter.

How has Big Pharma responded? By blaming others for making it set prices sky high. The 340B drug discount program is a favorite scapegoat. “The logic goes thusly: Since pharmaceutical companies must provide discounted medicines to 340B hospitals, they automatically raise prices on those drugs for everyone else to make up the difference,” write the directors of two cancer centers that depend on 340B savings in a new Morning Consult op-ed. “The problem? There are absolutely no data to back up the assertion. Even at a 20 to 50 percent discount to safety-net providers, drug makers often enjoy a sizeable profit. How much? We’ll never know because they guard that secret like the crown jewels.”

“We work for safety-net hospitals and it’s our mission to treat all patients who come through our doors,” write Dr. Mary Margaret Kemeny and Dr. Robert Chapman (the former is director of the Queens Cancer Center of Queens Hospital in Jamaica, N.Y.; the latter is director of the Josephine Ford Cancer Institute at the Henry Ford Health System in Detroit). “Savings from the 340B program help us provide diagnosis, medications and surgery to uninsured and underinsured individuals who would certainly die without medical intervention….And yet the drug industry continues to try and gut the program.”

Big Pharma’s $100 million ad campaign to restore its battered image “could buy 1,639,344 vials of cisplatin 50mg treatments for breast, ovarian, bladder and testicular cancer,” the physicians note.

“Imagine how many lives that could save.”

Recent Articles

  • HRSA Still Plans to Start Enforcing New 340B Regulation on April 1
  • Big Pharma Plays the Blame Game on Drug Prices
  • Report: Patient Groups Mum on High Drug Costs

Follow us on Twitter

340B HealthFollow

340B Health
340BHealth340B Health@340BHealth·
3h

When drug companies deny legally required #340B discounts, they are cutting off safety-net hospitals from significant savings that would be invested in vital health care services for patients in need. http://www.stop340bcuts.org #Protect340B

Reply on Twitter 1369011827523416071Retweet on Twitter 13690118275234160711Like on Twitter 13690118275234160712Twitter 1369011827523416071
340BHealth340B Health@340BHealth·
6h

Without #340B, kidney transplant patient Michael Hutson would struggle to cover a $500 co-pay to receive the medication he needs so his body doesn't reject the transplant. Michael shares his story: https://bit.ly/3v2t1yP #Facesof340B #NationalKidneyMonth #Protect340B

Reply on Twitter 1368964393711656965Retweet on Twitter 1368964393711656965Like on Twitter 1368964393711656965Twitter 1368964393711656965
340BHealth340B Health@340BHealth·
7 Mar

For many #uninsured patients, #340B means access to affordable #healthcare services that a safety-net hospital has the operational resources to provide through program savings. http://bit.ly/32J1uXk #Protect340B

Reply on Twitter 1368671570110119939Retweet on Twitter 1368671570110119939Like on Twitter 13686715701101199391Twitter 1368671570110119939
Load More...

RSS 340B Informed

  • Drug Giant’s Revenues Soar While 340B Cuts Sting
  • 340B Hospitals Are Key to the Pursuit of Health Equity
  • Senate Report Blasts Insulin Makers for High Prices

Copyright © 2021 · 340B Health